Table 1.
Antibiotic breakpoints for M. catarrhalis strains in EUCAST, CLSI and BSAC
| Antibiotics* | MICa/D-zoneb | EUCASTc | CLSId | BSACe | |||||
|---|---|---|---|---|---|---|---|---|---|
| S | R | S | I | R | S | I | R | ||
| AMP | MIC(mg/L) | -# | -# | -# | -# | -# | ≤1 | – | > 1 |
| AMC | MIC(mg/L) | ≤1 | >1 | ≤4 | – | ≥8 | ≤1 | – | > 1 |
| CXM | MIC(mg/L) | ≤4 | >8 | ≤4 | 8 | ≥16 | ≤1 | 2 | > 2 |
| CAZ | MIC(mg/L) | -# | -# | ≤2 | -# | -# | -# | -# | -# |
| FEP | MIC(mg/L) | ≤4 | >4 | -# | -# | -# | -# | -# | -# |
| CIP | MIC(mg/L) | ≤0.5 | >0.5 | ≤1 | -# | -# | ≤0.5 | – | > 0.5 |
| ERY | MIC(mg/L) | ≤0.25 | >0.5 | ≤0.5 | 1–4 | ≥8 | ≤0.25 | 0.5 | > 0.5 |
| MEM | MIC(mg/L) | ≤2 | >2 | -# | -# | -# | -# | -# | -# |
| TCY | D-zone(mm) | ≥28 | <25 | ≥29 | 25–28 | ≤24 | ≥22 | – | ≤21 |
| CHL | D-zone(mm) | ≥30 | <30 | -# | -# | -# | -# | -# | -# |
| SXT | D-zone(mm) | ≥18 | <15 | ≥13 | 11–12 | ≤10 | ≥12 | – | ≤11 |
aMIC minimum inhibitory concentration, bD-zone diameter of inhibition zone, cEUCAST, European Committee on Antimicrobial Susceptibility Testing, dCLSI Clinical and Laboratory Standards Institute, eBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints listed in the according criterion